Preemptive Therapy for High Risk Chronic Lymphoid Leukemia Stage A

NCT03766763 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

82

Enrollment

OTHER

Sponsor class

Conditions

Chronic Lymphoid Leukemia

Interventions

DRUG: Venetoclax

Sponsor

French Innovative Leukemia Organisation